Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Thompson, A; Sorensen, PS; Montalban, X; Cook, S; Goodkin D, Filippi M, Kappos L, Cohen J, Ebers G, Cutter G, Fazekas F, Barkhof F, Miller A, Brooks BR, Noseworthy J, Lucchinetti C, Weinshenker B.
Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis - Question and answer session.
MULT SCLER. 2004; 10 Suppl 1(1): S62; discussion 62-S62; discussion 64.
Doi: 10.1191/1352458504ms1033oa
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Fazekas Franz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- This short monograph describes a trial of interferon beta-1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon beta-1b 8 MIU given subcutaneously every other day for two years. Significant differences favouring interferon beta-1b in the MSFC score, T2 lesion volume and TI lesion volume at 24 months were observed. Further study of interferon beta-Ib therapy in PPMS patients in warranted.
- Find related publications in this database (using NLM MeSH Indexing)
- Adjuvants, Immunologic - therapeutic use
- Europe - therapeutic use
- Humans - therapeutic use
- Interferon-beta - therapeutic use
- Multiple Sclerosis, Chronic Progressive - drug therapy
- Pilot Projects - drug therapy